Effect and Safety of Flecainide and Metoprolol Versus Metoprolol Alone to Suppress Ventricular Arrhythmias in Arrhythmic Mitral Valve Prolapse

PHASE3RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 4, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Mitral Valve ProlapseVentricular Arrhythmias and Cardiac Arrest
Interventions
DRUG

Flecainide

Flecainide is mainly used for pharmacological conversion in patients with atrial tachyarrhythmias and to suppress ventricular arrhythmias in patients with structurally normal hearts.

DRUG

Metoprolol

Metoprolol is a beta-blocker and class II antiarrhythmic drug considered standard care in most cardiac diseases predisposing to ventricular arrhythmias, including arrhythmic mitral valve prolapse.

Trial Locations (1)

0372

RECRUITING

Oslo University Hospital Rikshospitalet, Oslo

All Listed Sponsors
collaborator

The Research Council of Norway

OTHER

collaborator

University of Oslo

OTHER

lead

Oslo University Hospital

OTHER